Clinical Trial Update: A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers [Phase 1]

View source ↗

Summary

Phase 1 trial to evaluate the safety and preliminary effectiveness of 27T51, a MUC16-targeting immune cell therapy, in adults with recurrent or treatment-resist…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Epithelial Cancer
• Peritoneal Cancer

Drugs mentioned

• 27T51

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma | Phase 1 | Status: RECRUITING